Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 20 - \<65 years,~* body mass index (BMI) ≥ 24 kg/m2,~* HbA1c ≥ 7% (53mmol/mol).~* diabetes antibodies (-)~* diagnosed with T2D within the previous 3 months~Exclusion Criteria:~* anti-diabetic drugs or diet therapy before participation~* pancreatitis~* coronary artery disease~* liver function impairment~* renal function impairment~* intestinal surgery~* chronic hypoxic diseases (emphysema and cor pulmonale)~* infectious disease~* hematological disease~* systemic inflammatory disease~* cancer~* pregnant, possibly pregnant~* ingesting agents known to influence glucose or lipid metabolism

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- exenatide group (Type: EXPERIMENTAL): The drug-naïve, overweight or obese patients with newly diagnosed T2D
- metformin group (Type: ACTIVE_COMPARATOR): The drug-naïve, overweight or obese patients with newly diagnosed T2D

Based on this trial design, predict the completion outcome and termination type (if applicable).